SF-6D utility index as measure of minimally important difference in health status change

We recommend using the MID range based on all patients combined (−0.03 to 0.10) to interpret SF-6D scores. These estimates can be used in conjunction with other measures of efficacy to determine meaningful changes. SF-6D demonstrates potential utility in predicting minimally important improvement or worsening among patients receiving different pharmacologic medications.